Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESENTATION - Cocrystal Pharma, Inc. | ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of
1934
Date of Report (Date of earliest event reported): January 9,
2017
Cocrystal Pharma,
Inc.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
000-55158
|
35-2528215
|
|
(State
or other Jurisdiction of Incorporation)
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
|
1860 Montreal Rd,
Tucker, GA
|
30084
|
|
(Address
of principal executive offices)
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (770) 892-8800
|
|
(Former
name or former address, if changed since last
report.):
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐ Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
☐ Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
☐ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
☐ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Item
7.01
Regulation FD Disclosure
Cocrystal Pharma,
Inc. (the “Company”) will be presenting information
about the Company’s antiviral therapies to investors in
connection with the 35th Annual J.P. Morgan
Healthcare Conference taking place in San Francisco, California
from January 9-13, 2017. A copy of the presentation is included as
an exhibit to this report. In addition, the presentation materials
may be accessed on the Company’s website,
www.cocrystalpharma.com, by selecting “News,” and then
“Presentations.”
Item
9.01
Financial Statements and Exhibits
(d)
Exhibits.
|
Exhibit
No.
|
|
Exhibit
|
|
99.1
|
|
Presentation dated
January 9, 2017
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
Cocrystal
Pharma, Inc.
Date: January 9,
2017
By: /s/ Walt A.
Linscott
Name:
Walt A. Linscott
Title:
General Counsel and Secretary